NEW YORK – BGI Genomics said on Thursday that it has received CE marking for two multiplexed tests for SARS-CoV-2 and influenza A/B produced by its subsidiary BGI PathoGenesis Pharmaceutical Technology.
Both real-time fluorescent RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples using a single reaction. One test detects the SARS-CoV-2 ORF1ab gene, while the second test detects the virus's ORF1ab and N genes.